Lung Tumor Protein Synthesis Rates in Lung Cancer Patients

Lung Cancer Clinical Trial

— LungMaas  

Official title:

Characterizing Tissue Protein Synthesis Rates of Non-small Cell Lung Carcinomas in Lung Cancer Patients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05794529
• Other study ID #: METCZ20220060
• Status: Recruiting
• Start date: March 2023
• Est. completion date: March 2026

Study information

• Verified date: March 2023
• Source: Maastricht University Medical Center
• Contact: Andrew Holwerda, PhD
• Phone: +31433881381
• Email: andy.holwerda[@]maastrichtuniversity.nl
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The current study will recruit lung cancer patients to measure tissue protein synthesis rates of non-small cell lung carcinomas and healthy lung tissue. The protein synthesis rates of healthy lung tissue will be compared to lung tumor tissue to establish the remodeling characteristics of healthy versus cancerous lung tissues. We will also examine whether tissue protein synthesis rates of non-small cell lung carcinomas are associated with various tumor- (i.e., size, subclassification) and patient-derived (i.e., inflammation, lung function, smoking status, and smoking history) parameters.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: March 2026
• Est. primary completion date: March 2026
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Aged 18-65 years

2. Compos mentis

3. Diagnosed with lung cancer, with treatment requiring a thoracotomy or VATS lobectomy

Exclusion Criteria:

1. Neoadjuvant chemo- or radiotherapy in the past four weeks

2. Use of systemic steroids in the past four week

3. Insulin-dependent diabetes mellitus

4. Pregnancy

Related Conditions & MeSH terms

• Lung Cancer
• Lung Neoplasms

Intervention

Other:
• There are no interventions in the present study
There are no interventions in the present study

Locations

Country	Name	City	State
Netherlands	Zuyderland Medical Center	Heerlen	Limburg

Sponsors (1)

Lead Sponsor	Collaborator
Maastricht University Medical Center

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Lung tumor fractional synthetic rate	units: % per day	5 days prior to surgery
Primary	Lung tissue fractional synthetic rate	units: % per day	5 days prior to surgery
Primary	Muscle tissue fractional synthetic rate	units: % per day	5 days prior to surgery
Secondary	Plasma glucose concentrations	units: mmol/L	Baseline
Secondary	Plasma insulin concentrations	units: pmol/L	Baseline
Secondary	Plasma GH concentrations	units: mU/L	Baseline
Secondary	Plasma IGF-1 concentrations	units: nmol/L	Baseline
Secondary	Plasma IGFBP-1 concentrations	units: ug/L	Baseline
Secondary	Plasma IGFBP-3 concentrations	units: ug/L	Baseline
Secondary	Plasma CRP concentrations	units: mg/L	Baseline
Secondary	Plasma IL-1 concentrations	units: ng/L	Baseline
Secondary	Plasma IL-6 concentrations	units: ng/L	Baseline
Secondary	Plasma IL-10 concentrations	units: ng/L	Baseline
Secondary	Plasma TNF-alpha concentrations	units: ng/L	Baseline